xBiotech USA, Inc.

115 articles about xBiotech USA, Inc.

• XBiotech Discovers COVID-19 Candidate TherapyThe Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood

  8/17/2020

  XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2, the virus that causes COVID-19. The Company discovered these antibodies through a collaboration with BioBridge Global (parent organization of the South Texas Blood & Tissue Center and QualTex Laboratories, one of the largest independent testing laboratories in the United States). For the c

• XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy

  7/22/2020

  XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in the development of its next generation inflammation-fighting True Human antibodies.

• XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke

  7/14/2020

  Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy

• XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy

  5/1/2020

  XBiotech Inc. (NASDAQ: XBIT) announced today that human immune donors have now been identified that can support the Company’s development of a True Human™ antibody therapy for COVID-19

• XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021

  4/14/2020

  XBiotech Inc. (NASDAQ: XBIT) announced today that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been advanced as a product candidate for clinical and commercial development. XBiotech discovered the IgG1 monoclonal antibody from a healthy donor with natural immunity against IL-1⍺. Creating medicines from natural human immunity is the hallmark of XBiotech’s approach to developing a new generation of break

• XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

  4/3/2020

  XBiotech Inc. and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration investigational program for U.S. blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.

• XBiotech Announces Final Results of Tender Offer

  2/19/2020

  AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the final count by American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, a total of 40,007,286 common shares, no par value, were properly tendered and not properly withdrawn at or below the maximum purchase price of $

• XBiotech Announces Preliminary Results of Tender Offer

  2/13/2020

  AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the preliminary count by American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, a total of 41,164,725 common shares of XBiotech were properly tendered and not properly withdrawn at or below the maximum purchase p

• Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer

  2/13/2020

  XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.

• XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares

  1/14/2020

  XBiotech Inc. announced that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than $30.00 nor greater than $33.00 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

• Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.

  12/30/2019

  The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million.

• XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

  12/30/2019

  Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline

• XBiotech Added to NASDAQ Biotechnology Index

  12/17/2019

  The addition to the NBI will become effective prior to market open on Monday, December 23, 2019.

• Janssen to Acquire Investigational Bermekimab from XBiotech

  12/7/2019

  Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa   [07-December-2019]   HORSHAM, Pa. , Dec. 7, 2019 /PRNewswire/ -- Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab

• XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

  12/7/2019

  XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen

• XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa

  11/19/2019

  Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS

• XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)

  11/12/2019

  Chaired by award-winning dermatologist Seth B. Forman, MD, of ForCare Medical Group in Tampa, FL, the study will assess weekly bermekimab therapy to reduce inflammatory skin lesions, itch, and pain in patients suffering from eczema.

• XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

  10/23/2019

  XBiotech Inc. announced that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen weeks of therapy.

• Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients

  7/9/2019

  Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”

• XBiotech Announces Presentation of Data From Phase II Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

  1/26/2018

  The study achieved its primary endpoint, showing significant treatment benefit using the HiSCR endpoint.